Corient Private Wealth
INBX icon

Corient Private Wealth’s Inhibrx INBX Stock Holding History

Corient Private Wealth’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71M Sell
28,653
-161
-0.6% -$16.1K ﹤0.01% 1189
2026
Q1 		$1.94M Buy
28,814
+8,371
+41% +$621K ﹤0.01% 1286
2025
Q4 		$1.61M Buy
+20,443
New +$1.39M ﹤0.01% 1258
2025
Q3 		– Sell
-20,455
Closed -$292K – 2623
2025
Q2 		$292K Hold
20,455
– – ﹤0.01% 2006
2025
Q1 		$286K Sell
20,455
-37
-0.2% -$502 ﹤0.01% 1880
2024
Q4 		$316K Buy
20,492
+6,667
+48% +$102K ﹤0.01% 1864
2024
Q3 		$217K Buy
+13,825
New +$194K ﹤0.01% 2194

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Corient Private Wealth's INBX Position: Q2 2026 in Review

Corient Private Wealth reduced its Inhibrx (INBX) stake by 0.56% in Q2 2026, selling an estimated $16.1K and leaving 28,653 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1189.

Corient Private Wealth first reported a position in INBX in Q3 2024 and has held it in 7 quarters since. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Corient Private Wealth held 28,653 shares of Inhibrx worth $2.71M as of Q2 2026.
  • Corient Private Wealth sold 161 Inhibrx shares in Q2 2026, an estimated $16.1K.
  • Inhibrx made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1189 holding.
  • Corient Private Wealth first reported a position in Inhibrx in Q3 2024 and has held it in 7 quarters since.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.